FTC Continues To Zero In On Problematic M&A Noncompetes
Third Circuit: “Rigorous Analysis” Required for Class Certification in Antitrust Cases
Bad Faith Required to Prevent Speech Regarding Potential Patent Infringement
Anticompetitive Conduct in Biologics – An Enforcement Priority with FTC and FDA
Anticompetitive Conduct in Biologics – An Enforcement Priority with FTC and FDA
Subscribe: Subscribe via RSS